Abstract Library

#3966 PTK2 PROTAC unveiled as a selective inhibitor of gastrointestinal neuroendocrine cell proliferation via multi-target drug screening

Introduction: Gastrointestinal neuroendocrine tumors (GI-NETs) exhibit a complex and diverse nature, posing challenges in their effective treatment and management. While there have been advancements in treatment options, addressing the need for more effective and targeted therapies remains a significant issue, especially for patients with advanced or metastatic disease. Improving outcomes in the management of patients with GI-NETs is a key priority, and further research and development are crucial in this regard.

Conference:

Presenting Author: Gagliano T

Authors: Malavasi E, Toffoli L, Dainotto M, Gagliano T,

Keywords: Protac, PTK2, Screening, GI-NETs,

#3551 Endoscopic ultrasonography and elastography in pancreatic and gastrointestinal neuroendocrine tumors diagnostic

Introduction: Endoscopic ultrasonography (EUS) is an examination using ultrasound and an endoscopic device, designed to image digestive tract and adjacent organs. The combination of EUS and elastography (EG) expands diagnostic and imaging capabilities.

Conference:

Presenting Author: Uhrík P

Authors: Uhrík P, Nosakova L, Pindura M, Miklušica J, Bánovčin P,

Keywords: pancreatic, gastrointestinal, neuroendocrine tumor, endoscopic ultrasound, elastography,

#3453 Comparison of Lanreotide and Octreotide LAR use and outcomes for gastrointestinal neuroendocrine tumors in British Columbia, Canada

Introduction: The long-acting somatostatin analogues (LA-SSAs) octreotide LAR (OCT) and lanreotide (LAN) improve progression-free survival in neuroendocrine tumors (NETs), however no head-to-head comparison exists. We compared treatment patterns and efficacy in a population-based cohort from British Columbia, Canada.

Conference:

Presenting Author: Paul A

Authors: Paul A, Mendis S, Jao J, Boutin M, Safro M,

Keywords: lanreotide, octreotide LAR, neuroendocrine tumor, overall survival,

#3175 Secondary primary cancers and survival among neuroendocrine tumor patients

Introduction: Higher rates of second cancer (SC) are suggested for patients with neuroendocrine tumors (NET), but data on SC are scare and their impact on outcomes is unknown.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Bateni S

Authors: Bateni S, Coburn N, Law C, Singh S, Myrehaug S,

Keywords: neuroendocrine tumor, secondary cancers, survival, gastrointestinal neuroendocrine tumor, pancreatic neuroendocrine tumor, pulmonary neuroendocrine tumor,

#2952 Genomic Landscape of Neuroendocrine Neoplasms from Gastrointestinal Tract, Pancreas, Lung, Rare and Unknown Primary Locations

Introduction: There are still few large-scale sequencing data to depict the genomic landscape of neuroendocrine neoplasms (NEN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Chen L

Authors: Chen L, Liu M, Zhang Y, Guo Y, Chen M,

Keywords: Genomics, neuroendocrine neoplasm, survival,